Implamedika - Company finances
|
EUR
|
2019
From: 2019-05-02
To: 2019-12-31
|
2020
From: 2020-01-01
To: 2020-12-31
|
2021
From: 2021-01-01
To: 2021-12-31
|
2022
From: 2022-01-01
To: 2022-12-31
|
2023
From: 2023-01-01
To: 2023-12-31
|
2024
From: 2024-01-01
To: 2024-12-31
|
2025
From: 2025-01-01
To: 2025-12-31
|
|---|---|---|---|---|---|---|---|
|
Financial data
|
|||||||
| Sales revenue | 150 | 180,297 | 642,964 | 1,069,891 | 1,453,416 | 1,618,698 | 1,798,828 |
| Profit before tax | -23,155 | -121,342 | 33,294 | 740 | 99,441 | 268,802 | 347,135 |
| Net profit | -23,155 | -121,342 | 31,199 | -1,232 | 84,380 | 219,060 | 279,693 |
| Equity | -20,655 | -141,997 | -110,798 | -112,030 | -27,650 | 191,410 | 471,103 |
| Liabilities | 752,541 | 1,581,792 | 1,740,797 | 1,713,030 | 1,522,987 | 1,456,688 | 1,329,412 |
| Non-current assets | 498,678 | 981,717 | 909,930 | 885,499 | 760,131 | 648,940 | 512,245 |
| Current assets | 233,132 | 458,003 | 719,967 | 706,942 | 734,661 | 997,039 | 1,290,739 |
| Total assets | 731,810 | 1,439,720 | 1,629,897 | 1,592,441 | 1,494,792 | 1,645,979 | 1,802,984 |
|
Taxes paid
|
|||||||
| STI taxes | - | - | - | - | 302,769 | 371,736 | 459,955 |
| Social insurance contributions | - | - | - | - | 34,100 | 39,533 | 41,106 |
|
Financial indicators
|
|||||||
| Revenue change y/y | - | +120098.0% | +256.6% | +66.4% | +35.8% | +11.4% | +11.1% |
| ROA Return on Assets (ROA). The ratio of net profit to assets. Indicates the company's efficiency. | -3.2% | -8.4% | 1.9% | -0.1% | 5.6% | 13.3% | 15.5% |
| ROE Return on equity. The ratio of net profit to equity. Shows the return to shareholders. | - | - | - | - | - | 114.4% | 59.4% |
| Profit margin Net profit margin. Shows the overall profitability of the company. | -15436.7% | -67.3% | 4.9% | -0.1% | 5.8% | 13.5% | 15.5% |
| EBT% EBT (Earnings Before Taxes) to revenue ratio. Shows the overall profitability of the company. | -15436.7% | -67.3% | 5.2% | 0.1% | 6.8% | 16.6% | 19.3% |
| Liabilities/Equity The debt-to-equity ratio shows the company's capital structure. | - | - | - | - | - | 7.6 | 2.8 |
| Revenue per employee Ratio of revenue to the average annual number of employees. Indicates company efficiency. | 150 | 113,874 | 220,442 | 267,473 | 341,980 | 323,740 | 431,715 |
Sales revenue
See Scoris data in Google Search
Mark Scoris as a favorite source. One click, no registration.
Implamedika - Social security debts
| From | To | Debt, € |
|---|---|---|
| 2025-12-16 | 2025-12-16 | 2476.49 |
| 2025-04-16 | 2025-04-21 | 593.53 |
| 2025-02-18 | 2025-02-18 | 1.46 |
| 2023-08-17 | 2023-08-22 | 7.46 |
| 2023-07-28 | 2023-08-13 | 7.46 |
| 2023-07-24 | 2023-07-25 | 7.72 |
| 2023-06-16 | 2023-06-25 | 2339.47 |
| 2023-05-02 | 2023-05-07 | 0.05 |
| 2023-04-18 | 2023-04-28 | 0.05 |
| 2023-03-16 | 2023-04-04 | 0.05 |
| 2023-02-17 | 2023-03-05 | 0.05 |
| 2023-02-06 | 2023-02-06 | 0.05 |
| 2023-01-24 | 2023-02-03 | 0.05 |
| 2022-10-18 | 2022-10-19 | 57.26 |
Implamedika - VMI tax arrears
| From | To | Overdue, € |
|---|---|---|
| 2025-12-15 | 2025-12-15 | 768.03 |
| 2025-07-24 | 2025-07-25 | 0.48 |
VMI debt information has been collected since 2024-10-07. Debts for older periods will not be displayed.
Analysis of the company's financial position
This description was generated by artificial intelligence.
Report if inaccurate.
Implamedika, UAB (company code 305151952) is a Private Limited Liability Company engaged in medical specialists activities. In 2025, the company generated revenue of €1.80M, up 11.1% year on year and 23.8% over two years. Profitability remained strong, with net profit rising to €279.7K in 2025 from €219.1K in 2024 and €84.4K in 2023. The 2025 net profit margin was 15.6%, reflecting improved efficiency alongside growth in turnover. The balance sheet also strengthened: total assets increased to €1.80M, equity reached €471.1K, and liabilities stood at €1.33M. Long-term assets declined from €760.1K in 2023 to €512.2K in 2025, while short-term assets increased to €1.29M, indicating a shift toward more liquid resources. Key ratios for 2025 show ROE of 59.4%, ROA of 15.5%, debt-to-equity of 2.82, and asset turnover of 1.00x. Revenue per employee was €449.7K and profit per employee was €69.9K, pointing to solid productivity.